- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00229463
Study of Genetic Differences in People With Depression (Genetics)
November 16, 2016 updated by: Andrew F. Leuchter, University of California, Los Angeles
The purpose of this study is to identify genes involved in depression.
Specifically, the investigators will analyze some genes that may be related to whether or not a person responds to antidepressant medication.
This project is part of basic scientific research to increase understanding of the role of genetic influences in psychological and mental processes involved in the response to treatment for depression.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90024
- UCLA Semel Institute for Neuroscience and Human Behavior
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients will be recruited from previous studies conducted at the Laboratory of Brain, Behavior, and Pharmacology, where subjects' response to treatment has already been determined.
This strategy offers the advantage that no new subjects need to be enrolled in placebo-controlled treatment studies.
Description
Inclusion Criteria:
- History of Unipolar Major Depression
- Control subjects must be healthy normal adults
Exclusion Criteria:
- Subjects with mood symptoms that are not severe enough to qualify for MDD
- Subjects with any active medical illness that may be related to ongoing mood disorder
- Normal subjects must be free from: a psychiatric diagnosis, substance abuse, a history of seizure disorder, and any serious medical illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Andrew F. Leuchter, M.D., University of California, Los Angeles
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2002
Primary Completion (Actual)
January 1, 2011
Study Completion (Actual)
January 1, 2011
Study Registration Dates
First Submitted
September 28, 2005
First Submitted That Met QC Criteria
September 28, 2005
First Posted (Estimate)
September 29, 2005
Study Record Updates
Last Update Posted (Estimate)
November 18, 2016
Last Update Submitted That Met QC Criteria
November 16, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-10-049
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Gang WangWest China Hospital; The First Hospital of Hebei Medical University; Tianjin... and other collaboratorsRecruitingMajor Depressive Disorder (MDD) | Depression - Major Depressive DisorderChina
-
Brian MickeyNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Episode | Depression - Major Depressive Disorder | Treatment-Resistant Major Depressive DisorderUnited States
-
Unity Health TorontoUniversity of Toronto; Toronto Metropolitan UniversityRecruitingMajor Depressive Disorder (MDD) | Major Depressive Episode | Treatment-Resistant Major Depressive DisorderCanada
-
Stanford UniversityNational Institute of Mental Health (NIMH)Recruiting
-
TakedaRecruitingMajor Depressive DisorderJapan
-
Neurocrine BiosciencesRecruitingMajor Depressive DisorderSpain, Serbia, United States, Bulgaria, Canada, Estonia, Italy, Poland, Taiwan, Australia, South Korea
-
Luye Pharma Group Ltd.Enrolling by invitationMajor Depressive DisorderChina
-
NeuroQore Inc.Makromed Inc.Enrolling by invitationMajor Depressive DisorderUnited States
-
The Royal Ottawa Mental Health CentreNot yet recruitingDepression | Major Depressive Disorder (MDD) | Depressive Episode | Depression - Major Depressive DisorderCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael